The MT-101-101 study is a phase 1 clinical trial (first-time in humans). It will test the safety and dosing of a new treatment designed to stop or reduce the immune attack on the pancreas that causes type 1 diabetes.

Participants in this study will be aged 18-45, currently managing their diabetes with insulin and have a recent blood test to confirm residual c-peptide (measure of insulin production).

Participants in the MTX-101-101 study will attend 15-19 visits to the clinical centre over 6 months. The results of this study will assist researchers to determine the optimal dose for future trials and participants will be reimbursed for their travel.